KRW 100 billion Viread market preoccupied by Chong Kun Dang
Chong Kun Dang has took a step forward for commercialization of an incrementally modified drug of Viread(generic name: tenofovir), a chronic hepatitis B treatment.
The Ministry of Food and Drug Safety(MFDS) approved a Phase 3 clinical trial approval of a Viread-modified drug, CKD-390,’ develope...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
